Individualizing Dual Antiplatelet Therapy (DAPT) Duration Based on Bleeding Risk, Ischemic Risk, or Both: An Analysis From the DAPT Study

Mihatov, N., Secemsky, E. A., Kereiakes, D. J., Steg, P. G., Cutlip, D. E., Kirtane, A. J., Mehran, R., Zhao, B., Song, Y., Gibson, C. M., & Yeh, R. W. (2022). Individualizing Dual Antiplatelet Therapy (DAPT) Duration Based on Bleeding Risk, Ischemic Risk, or Both: An Analysis From the DAPT Study. Cardiovascular Revascularization Medicine, 41, 105–112. https://doi.org/10.1016/j.carrev.2022.01.006

Authors:

Nino Mihatov

Eric A. Secemsky

Dean J. Kereiakes

P. Gabriel Steg

Donald E. Cutlip

Ajay J. Kirtane

Roxana Mehran

Bokai Zhao

Yang Song

C. Michael Gibson

Robert W. Yeh